Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook

Published by	Business Insights
Published	October, 2009	Product code	103269
Content info	141 pages
Price	US $ 3835 PDF by E-mail (Single User License) US $ 14381 PDF by E-mail (Global Site License)

Introduction
Related Reports

Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook published by Business Insights in October, 2009. This report consists of 141 pages and the price starts from US $ 3835.

Introduction

Abstract

Despite public policy measures to prevent cancer, such as tobacco control and vaccination against HPV, cancer is sure to remain a significant public health problem throughout the 21st century. Indeed, the global demographic shift towards an ageing population and the spread of high tech modern medicine throughout the emerging economies of Asia and (maybe later) Africa, will expand the market for cancer diagnostics globally. Major developments are likely in both the IVD market and in imaging-based modalities, like computed tomography, with the emphasis being upon the personalized medicine approach, where demand will come from physicians, patients and payors - all of whom want more effective treatments and value for money. ' Innovations in Oncology Diagnostics' is a new report published by Business Insights that analyzes the latest innovations in oncology diagnostics and identifies the most exciting new technologies and trends, ranging from body imaging and cytology to molecular diagnostics and pharmacogenomics. This report also identifies the key challenges facing innovative diagnostics companies.

Executive summary

Setting the scene
Innovations in diagnostic imaging
Innovations in molecular diagnostics
Innovations in pharmacogenomics
Challenges in the oncology diagnostics sector
Competitive landscape

Chapter 1 Setting the scene

Summary
Introduction
- Cancer facts, current and projected
- History of oncology diagnostics
- Elements of a cancer diagnosis
- Pathology
Oncology diagnostics market

Chapter 2 Innovations in diagnostic imaging

Summary
Introduction
Body imaging
- Overview
- X-ray
  - Breast cancer
- Computed tomography
  - Lung cancer
  - Colon cancer
  - Others
- Ultrasound
- Magnetic resonance imaging
- Nuclear medicine - PET & SPECT
- Case study
  - HYPERImage
Cytology
- Overview
- Flow cytometry
- Case study
  - CellSearch
- Cervical screening
- Cytogenetics

Chapter 3 Innovations in molecular diagnostics

Summary
Introduction
DNA, genes and chromosomes
- Fluorescence in situ hybridization (FISH)
- PCR and variants
- Case study
  - HPV testing
Immunoassays and biomarkers
- Case study
  - Ovarian cancer
  - PSA testing
- Other areas of research
Epigenomics
Microarrays
- Comparative genomic hybridization (CGH)
- Case study
  - Almac
  - DiaGenic
Overview of clinical applications of molecular diagnostics
- BCR-ABL
- LOH
- MSI

Chapter 4 Innovations in pharmacogenomics

Summary
Introduction
Familial cancer
- Breast cancer
- Colon cancer
- Melanoma
- Case study
  - IP challenge
Response to therapy
- Cytochrome P450 variants
- HER2 overexpression
The FDA, EMEA and PGx labeling
- Case study
  - TheraScreen: KRAS
  - BioTheranostics: Breast cancer
  - Clarient: Breast cancer
  - Marker validation for erlotinib in lung cancer
Companion diagnostics

Chapter 5 Challenges in the oncology diagnostics sector

Summary
Introduction
Reimbursement funding
- Educated patients = educated decisions
- Regulation
- Pharmacoeconomics
Emerging markets
Partnerships between drug companies & academia
Research & development
Mergers & acquisitions

Chapter 6 Competitive landscape

Summary
Introduction
Abbot Diagnostics
Affymetrix
Beckman Coulter
Becton Dickinson
Bio-Rad Laboratories
Gen-Probe
Johnson & Johnson (J&J)
- Ortho Clinical Diagnostics
Luminex
- Tm Bioscience
Nanogen
Roche Diagnostics
Siemens Healthcare Diagnostics
Sysmex
Future perspectives in the oncology diagnostics market
- Science
- Infrastructure
- Adoption of innovation
- Companion diagnostics

Chapter 7 Appendix

Glossary
Index

List of Figures

Figure 1.1: Leading sites of new cancer US, 2009
Figure 1.2: Leading sites of new cancer in developing countries, 2007
Figure 1.3: Information required by oncologist pre/post diagnosis
Figure 1.4: Oncology diagnostics forecasts ($bn), 2007-14
Figure 2.5: Example of the use of 3D tomosynthesis imaging
Figure 2.6: Number of CT scans in the US, 1995-2008
Figure 2.7: Women having mammograms (%) in the US, 2004*
Figure 2.8: Global flow cytometry market forecast ($bn), 2008-14
Figure 3.9: IV diagnostics market forecast ($bn), 2007-2014)
Figure 3.10: Use of biomarkers
Figure 3.11: Obstacles to biomarker development
Figure 3.12: US 5-year survival (%) for ovarian cancer at time of diagnosis
Figure 4.13: Myriad: Molecular diagnostics sales ($m), 2005-09
Figure 4.14: Number of biologics regulated by CDER that have existing PGx information
Figure 4.15: Herceptin therapy cost ($) per patient relative to HER2 testing
Figure 5.16: Decline in S&P global sector indices (%), 12 months to December 2008
Figure 5.17: IV diagnostics risk-based classification
Figure 5.18: FDA validated biomarkers by therapeutic area, September 2009
Figure 5.19: Roche Diagnostics regional sales (CHFm), 2008
Figure 5.20: Leading diagnostic firms increase in R&D spend (%) y-o-y, 2008

List of Tables

Table 1.1: WHO cancer mortality forecasts by region (' 000), 2008-30
Table 1.2: In vitro diagnostics market forecast ($bn), 2008-14
Table 2.3: Overview of imaging systems
Table 2.4: Mortality reduction (%) attributed to FOBT screening, 1985-96
Table 2.5: Organ radiation data from various clinical studies
Table 3.6: Extensively investigated cancer biomarkers
Table 3.7: Market potential for Epigenomics' cancer specialty tests
Table 4.8: Absent/incomplete efficacy (%) of drugs by therapeutic class
Table 5.9: Leading M&A deals in the diagnostics industry ($m), 2009
Table 6.10: Sales for the leading innovative oncology diagnostics companies ($m), 2006-08
Table 6.11: Beckman Coulter R&D investment ($m), 2004-08
Table 6.12: Bio-Rad sales ($bn) 2004-2008
Table 6.13: Roche Diagnostics sales by division (CHFm), H109
Table 6.14: Major recent Dx-Rx partnerships